TrialMolecular oncology2025

Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.

Andreas Ullern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.